Robot-assisted brain angiography was faster than manual - and just as safe

Digital subtraction angiography is the gold standard for diagnosing cerebrovascular diseases - aneurysms, arteriovenous malformations, arterial stenosis. But it comes with an occupational hazard. The procedure requires neurosurgeons to work under fluoroscopic guidance, standing in the radiation zone while threading catheters through blood vessels in the brain. Over a career, that cumulative exposure adds up.

Robotic systems promise to change this equation by letting surgeons operate catheters remotely, from outside the radiation field. Several systems exist worldwide, but real-world clinical data has been scarce - particularly for domestically produced Chinese systems entering an increasingly competitive market.

A study published in the Chinese Neurosurgical Journal provides the first clinical evaluation of the YDHB-NS01, a Chinese-made robot-assisted system for cerebral angiography. The results, from 50 consecutive procedures performed at Peking Union Medical College Hospital, suggest the robot works at least as well as manual technique - and possibly faster.

27 minutes versus 38

Dr. Yuanli Zhao and his team prospectively enrolled 25 patients for robot-assisted cerebral angiography and 25 for conventional manual angiography between May and August 2025. A single neurosurgeon performed all procedures, eliminating operator variability.

Every procedure succeeded. Both groups achieved 100% technical and clinical success rates, with all target vessels clearly visualized to diagnostic standards.

The standout difference was speed. Median procedure time in the robotic group was 27 minutes, compared to 38 minutes in the manual group - a statistically significant 11-minute reduction (p = 0.005). Fluoroscopy time, patient radiation dose, contrast agent volume, and total angiography room time showed no significant differences between the groups.

Zero complications occurred in any of the 50 patients. No puncture-related problems, no vessel spasm or perforation, no thromboembolism, no neurological events, no contrast reactions.

The learning curve shows

The data did reveal a learning curve. The first two robot-assisted cases required longer procedure times and higher radiation doses than subsequent cases. After those initial procedures, the remaining 23 showed more stable parameters. This is typical for new surgical technology and suggests that the speed advantage would likely increase as operators gain experience.

Operator evaluations were positive. Surgeons reported smooth catheter and guidewire delivery, stable manipulator fixation, responsive control handles, and good force feedback. The robotic system operated without mechanical or software failures throughout the study.

Small study, big caveats

Zhao was straightforward about the study's limitations. This was a single-center, 50-patient case series - not a randomized controlled trial. The sample size is too small to draw definitive conclusions about safety or efficacy, and results from one institution with one experienced surgeon may not generalize to other settings or operators.

The study also focused exclusively on diagnostic angiography, which is a relatively straightforward procedure. The more challenging application - robot-assisted therapeutic intervention, where catheters deliver treatments rather than just images - was not evaluated. Whether the YDHB-NS01 can perform reliably in more complex neurovascular interventions remains an open question.

The literature review included in the paper summarizes the broader state of robotic neurointervention, noting ongoing challenges across all platforms: improving force feedback (the tactile sense that tells surgeons how much resistance they are encountering), optimizing imaging integration, and ensuring compatibility with the full range of commercial catheters and guidewires used in neurovascular procedures.

Where robot-assisted angiography fits

The primary benefit of robotic angiography is not to the patient - whose outcomes in this study were identical regardless of method - but to the surgeon. Moving the operator outside the radiation zone eliminates a significant occupational health risk. If the procedure is also faster, that is a bonus for scheduling efficiency and operating room throughput.

Whether this translates to widespread adoption depends on factors beyond clinical performance: cost, training requirements, workflow integration, and regulatory approval in different markets. Larger multicenter trials will be needed before the YDHB-NS01 or any similar system becomes a standard tool in neurovascular suites.

But as proof of concept, the data is clean. One hundred percent success, zero complications, shorter procedures, no added radiation. For a first clinical evaluation, that is a solid starting point.